On this page you will find information for pharmacists involved in the RECOVERY Trial, including FAQs and HRA Pharmacy Assurance.
December 2022: RECOVERY trial sotrovimab has received a further expiry date extension, to 30 months. This will require relabelling existing stock and any new stock received. Please see sotrovimab 30 month expiry documents below.
December 2022: We are aware that some packs of molnupiravir and Paxlovid used in RECOVERY currently have a short shelf life. RECOVERY uses NHS stocks of these antivirals, and the DHSC is currently arranging batch specific variations to extend shelf life for both.